Biomarker Detection_上海瀚枢生物医药有限公司

Cn

Cn

About us

Company Introduction

Equipments & Facilities

History

Core Strengths

Qualifications & Awards

Our Partner

Therapeutic Area

CNS Disease

Mental Illness

Depression Disorder

Anxiety Disorder

Schizophrenia

Neurodegenerative Disease

Alzheimer's Disease (AD)

Parkinson's Disease (PD)

Amyotrophic Lateral Sclerosis (ALS)

Pain Disorders

Inflammatory Pain

Neuropathic Pain

Postoperative Pain

Sleep and Seizure Disorders

Sleep Disorder

Epilepsy

Brain Cancers

Primary Tumor (Gliomas)

Metastatic Brain Tumor

Neurovasculor Disease

Stroke

Hypertensive Encephalopathy

Addiction and Anesthesia

Drug Addiction

General Anesthesia

Non-CNS Diseases

Reproduction-Related Model

Menopause-Related Model

Service & Platfroms

Service

Pharmacokinetics (PK)

Ex Vivo P-gp / BCRP Substrate Assessment System

Ex Vivo Pharmacology

In Vivo Pharmacodynamics (PD)

CNS Safety Pharmacology

Target Validatio

Human Deried Stem Cell And Organoids

iPS Cell-Derived Differentiated Cells

Organoids

Platfrom

Behavioral Analysis

Electrophysiology

Biomarker Evaluation

AI-Driven Phenotypic Screening

Multi-Dimensional Surgery and Imaging

In Vitro Immunological Activity Evaluation of TCE Drugs

News & Events

Contact us

Join us
Therapeutic Area
Front Page > Therapeutic Area > Neurodegenerative Disease > Alzheimer's Disease (AD) > Evaluation Paradigm
Alzheimer's Disease (AD)
Animal Models
Evaluation Paradigm
Biomarker Detection

- Amyloid Plaque

- Soluble Aβ Measurement

- BrdU Incorporation-Based Cell Proliferation Measurement

- Synaptic Plasticity: Long-Term Potentiation / Long-Term Depression (LTP/LTD)

- PK Studies in Small Animals and Large Animals